Literature DB >> 31884197

The association between total serum isomers of per- and polyfluoroalkyl substances, lipid profiles, and the DNA oxidative/nitrative stress biomarkers in middle-aged Taiwanese adults.

Chien-Yu Lin1, Hui-Ling Lee2, Yi-Ting Hwang3, Ta-Chen Su4.   

Abstract

Per- and polyfluoroalkyl substances (PFAS) have been widely used in consumer products. In vitro and animal studies have demonstrated that exposure to perfluorooctanoic acid (PFOA) and/or perfluorooctane sulfonate (PFOS) increases oxidative/nitrative stress. Recent studies have also found that isomers of PFOA/PFOS may have unique biological effects on clinical parameters. However, the correlation between PFOA/PFOS isomers and markers of oxidative/nitrative stress has never been investigated in the general population. In the current study, 597 adult subjects (ages between 22 and 63 years old) were enrolled from a control group of a case-control study entitled "Work-related risk factors and coronary heart disease". We investigated the correlation between the serum isomers of PFOA/PFOS, lipid profiles, and the urine compounds 8-hydroxy-2-deoxyguanosine (8-OHdG) and 8-nitroguanine (8-NO2Gua) in these participants. There were 519 men and 78 women with a mean age of 45.8 years. Linear PFOA levels were positively correlated with serum low density lipoprotein cholesterol (LDL-C), small dense LDL, and triglyceride, and linear PFOS levels were positively correlated with LDL-C and HDL-C in multiple linear regression analyses. After controlling for potential confounders, the mean levels of 8-OHdG and 8-NO2Gua significantly increased across the quartiles of linear PFOS in multiple linear regression analyses. When both the 8-OHdG and 8-NO2Gua levels were above the 50th percentile, the odds ratio (OR) of higher levels of LDL-C (>75th percentile) with one unit increase in ln linear PFOS level was the highest (OR 3.15 (95% CI = 1.45-6.64), P = 0.003) in logistic regression models. In conclusion, serum linear PFOA/PFOS were correlated with lipid profiles, and linear PFOS was associated with urine oxidative/nitrative stress biomarkers. The positive correlation between linear PFOS and LDL-C was more marked when concentrations of urine oxidative/nitrative stress biomarkers were elevated. Further studies are needed to elucidate the causal relationships among PFAS isomers, lipid profiles, and oxidative/nitrative stress.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  8-Hydroxy-2-deoxyguanosine (8-OHdG); 8-Nitroguanine (8-NO2Gua); Per- and polyfluoroalkyl substances (PFAS); Perfluorooctane sulfonate (PFOS); Perfluorooctanoic acid (PFOA)

Mesh:

Substances:

Year:  2019        PMID: 31884197     DOI: 10.1016/j.envres.2019.109064

Source DB:  PubMed          Journal:  Environ Res        ISSN: 0013-9351            Impact factor:   6.498


  4 in total

Review 1.  Oxidative-Antioxidant Imbalance and Impaired Glucose Metabolism in Schizophrenia.

Authors:  Amira Bryll; Justyna Skrzypek; Wirginia Krzyściak; Maja Szelągowska; Natalia Śmierciak; Tamas Kozicz; Tadeusz Popiela
Journal:  Biomolecules       Date:  2020-03-02

2.  Health consequences of disinfection against SARS-CoV-2: Exploring oxidative stress damage using a biomonitoring approach.

Authors:  Ata Rafiee; Juana Maria Delgado-Saborit; Peter D Sly; Hoda Amiri; Shamim Mosalaei; Mohammad Hoseini
Journal:  Sci Total Environ       Date:  2022-01-02       Impact factor: 7.963

3.  Analysis of 19 urinary biomarkers of oxidative stress, nitrative stress, metabolic disorders, and inflammation using liquid chromatography-tandem mass spectrometry.

Authors:  Maria-Pilar Martinez-Moral; Kurunthachalam Kannan
Journal:  Anal Bioanal Chem       Date:  2022-01-11       Impact factor: 4.142

4.  Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; T Hyötyläinen; T Sinioja; C Boston; H Puckett; J Oliver; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2021-07-10       Impact factor: 4.460

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.